Emanuele Zucca

Q: What Schools Are Affiliated With Emanuele Zucca

Emanuele Zucca is affiliated with the following schools: University of Insubria, Università della Svizzera italiana, University of Milan, University of Verona, University of Bern, Sapienza University of Rome, University of Barcelona, University of Bologna, University of Zurich, King's College London

Emanuele Zucca's AcademicInfluence.com Rankings

Emanuele Zucca

Philosophy

#6272

World Rank

#9279

Historical Rank

Logic

#3452

World Rank

#4610

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Emanuele Zucca's Degrees

PhD Biomedical Sciences University of Milan
Doctorate Medicine University of Milan

Why Is Emanuele Zucca Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Emanuele Zucca's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised response criteria for malignant lymphoma. (2007) (4137)
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) (1153)
Accurate photometric redshifts for the CFHT legacy survey calibrated using the VIMOS VLT deep survey (2006) (1054)
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. (2003) (653)
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. (2005) (650)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004) (582)
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1 (2004) (552)
A test of the nature of cosmic acceleration using galaxy redshift distortions (2008) (550)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial (2009) (547)
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. (2003) (474)
Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue (1995) (457)
Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. (2007) (419)
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. (2003) (399)
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. (2003) (387)
Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. (1997) (384)
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. (2016) (374)
zCOSMOS – 10k-bright spectroscopic sample - The bimodality in the galaxy stellar mass function: exploring its evolution with redshift (2009) (331)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. (2016) (297)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. (2016) (280)
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. (2013) (280)
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. (2005) (252)
Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. (1998) (246)
Patterns of survival in mantle cell lymphoma. (1995) (241)
Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. (2000) (236)
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. (2010) (233)
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. (2008) (231)
The VIMOS-VLT deep survey - Evolution of the galaxy luminosity function up to z = 2 in first epoch data (2004) (226)
Epidemiology of hematological malignancies. (2007) (224)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs (2015) (220)
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma (2006) (208)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. (2013) (204)
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. (2013) (202)
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. (2008) (200)
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome (2009) (193)
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. (1997) (190)
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. (2016) (186)
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. (2018) (183)
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. (2003) (179)
Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. (1999) (172)
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. (2011) (170)
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. (2007) (168)
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. (2002) (168)
The gastric marginal zone B-cell lymphoma of MALT type (2000) (166)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. (2011) (163)
European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) (1994) (162)
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. (2017) (160)
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. (2012) (153)
Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. (2003) (153)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). (2015) (150)
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (144)
Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? (2007) (140)
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. (2001) (139)
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. (2014) (138)
Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. (2009) (133)
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (131)
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. (2015) (129)
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study (2009) (128)
A MALT lymphoma prognostic index. (2017) (127)
Localized non‐Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients (2001) (125)
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. (2004) (125)
Relevance of intraocular involvement in the management of primary central nervous system lymphomas. (2002) (124)
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (116)
The gastric marginal zone B-cell lymphoma of MALT type. (2000) (114)
State-of-the-art therapeutics: marginal-zone lymphoma. (2005) (112)
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. (2002) (110)
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
Update on the molecular biology of mantle cell lymphoma (2006) (109)
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. (2008) (109)
Molecular basis of mantle cell lymphoma (2004) (108)
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma (2007) (107)
How I treat mantle cell lymphoma. (2009) (104)
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. (2008) (102)
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. (2009) (101)
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. (2013) (100)
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (2001) (98)
B‐CELL LYMPHOMA OF MALT TYPE: A REVIEW WITH SPECIAL EMPHASIS ON DIAGNOSTIC AND MANAGEMENT PROBLEMS OF LOW‐GRADE GASTRIC TUMOURS (1998) (95)
Incidence, risk factors and outcome of histological transformation in follicular lymphoma (2012) (95)
Direct sequence analysis of the 14q+ and 18q- chromosome junctions in follicular lymphoma. (1990) (95)
Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. (2009) (94)
Primary and secondary bone lymphomas. (2015) (90)
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (88)
The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma (2008) (88)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. (2017) (85)
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). (2011) (82)
Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas (2014) (81)
Histologic transformation in marginal zone lymphomas†. (2015) (80)
The VIMOS-VLT deep survey Color bimodality and the mix of galaxy populations up to z ∼ 2 (2006) (78)
Physical properties of galaxies and their evolution in the VIMOS VLT Deep Survey - I. The evolution of the mass-metallicity relation up to z ~ 0.9 (2008) (76)
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial (2010) (75)
Marginal zone lymphomas. (2008) (75)
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. (2005) (75)
Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice (2013) (74)
Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion (2008) (72)
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy (2017) (71)
Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. (2013) (71)
Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. (2000) (70)
Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. (2001) (68)
Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? (2008) (68)
High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. (1995) (68)
Flows and flaws in primary central nervous system lymphoma (2010) (66)
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. (2018) (64)
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). (2014) (64)
MALT lymphomas: pathogenesis can drive treatment. (2011) (63)
Primary Bone Marrow Lymphoma: An Uncommon Extranodal Presentation of Aggressive Non-Hodgkin Lymphomas (2012) (63)
Reactive perivascular T‐cell infiltrate predicts survival in primary central nervous system B‐cell lymphomas (2007) (62)
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. (2020) (62)
Delving deeper into MALT lymphoma biology. (2005) (60)
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial (2009) (60)
Primary testicular lymphoma. (2008) (60)
Genetic lesions in diffuse large B-cell lymphomas. (2015) (60)
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma (2018) (59)
Marginal-zone lymphoma. (2007) (59)
The VIRMOS deep imaging survey IV: Near-infrared observations (2005) (58)
Extranodal lymphoma: a reappraisal. (2008) (58)
Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review (2008) (57)
The landscape of new drugs in lymphoma (2017) (57)
The VVDS-SWIRE-GALEX-CFHTLS surveys: physical properties of galaxies at z below 1.2 from photometric data (2008) (57)
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) (2014) (56)
Detection rate of fluorine‐18‐fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta‐analysis (2015) (56)
Comparative genome‐wide profiling of post‐transplant lymphoproliferative disorders and diffuse large B‐cell lymphomas (2006) (56)
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. (2014) (56)
Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. (1998) (55)
Genome wide DNA‐profiling of HIV‐related B‐cell lymphomas (2010) (55)
Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. (2011) (55)
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. (2018) (55)
Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21 (2010) (55)
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma (2013) (52)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) (2021) (51)
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B‐cell lymphomas (2010) (51)
Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features (2010) (50)
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. (2016) (50)
Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma (2010) (50)
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. (2015) (50)
Pathobiology of Primary Mediastinal B-Cell Lymphoma (2003) (50)
Genome‐wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia (2011) (49)
Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP (2011) (48)
Primary extranodal B-cell lymphoma: current concepts and treatment strategies. (2015) (48)
Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process (1997) (48)
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. (2013) (47)
The VVDS-VLA Deep Field II. Optical and near infrared identifications of VLA S(1.4GHz)>80 microJy sources in the VIMOS VLT Deep Survey VVDS-02h field (2005) (47)
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas (2015) (46)
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses (2019) (46)
Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature (1998) (46)
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix) (2016) (46)
Rituximab: 13 open questions after 20years of clinical use. (2017) (45)
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) (1999) (45)
The NF-B negative regulator TNFAIP 3 ( A 20 ) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas (2009) (44)
Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. (1998) (43)
Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. (1999) (43)
Genomic profiles of MALT lymphomas: variability across anatomical sites (2011) (43)
Physical properties of galaxies and their evolution in the VIMOS VLT Deep Survey. II. Extending the mass-metallicity relation to the range z ≈ 0.89-1.24 (2008) (43)
Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (43)
Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis. (1993) (43)
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas (2015) (43)
MYD88 somatic mutations in MALT lymphomas (2012) (42)
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG) (2016) (42)
Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. (1994) (42)
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. (2019) (41)
Clinical aspects and therapy of gastrointestinal MALT lymphoma. (2017) (40)
The VIMOS VLT Deep Survey: the faint type-1 AGN sample (2006) (40)
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. (2016) (40)
Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment (2008) (39)
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma (2017) (37)
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia (2011) (37)
Management of the marginal zone lymphomas. (2015) (37)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). (2015) (37)
The VIMOS Integral Field Unit: Data‐Reduction Methods and Quality Assessment (2005) (37)
Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients (2007) (36)
Splenic marginal zone lymphoma: current knowledge and future directions. (2012) (36)
Treatment of extranodal lymphomas. (2002) (36)
Eddington ratios of faint AGN at intermediate redshift: evidence for a population of half-starved black holes (2008) (36)
Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis (2019) (36)
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) (2014) (35)
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. (2020) (35)
Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (2014) (35)
Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. (2012) (35)
Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (34)
Patterns of survival of follicular lymphomas at a single institution through three decades (2010) (34)
Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. (2012) (34)
Recent advances in understanding the biology of marginal zone lymphoma (2018) (34)
Biology and treatment of MALT lymphoma: the state-of-the-art in 1996. A workshop at the 6th International Conference on Malignant Lymphoma. Mucosa-Associated Lymphoid Tissue. (1996) (33)
The management of nongastric MALT lymphomas. (2014) (33)
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma (2003) (33)
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. (2007) (32)
High density genome‐wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia (2008) (32)
T-Cell Lymphomas in South America and Europe (2012) (32)
Risk factors of central nervous system relapse in mantle cell lymphoma (2013) (32)
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study (2018) (31)
The VIMOS-VLT Deep Survey (VVDS) - The dependence of clustering on galaxy stellar mass at z ~ 1 (2008) (31)
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (2004) (31)
Life expectancy of young adults with follicular lymphoma. (2015) (31)
A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function (2008) (30)
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. (2011) (30)
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. (2017) (30)
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents (2019) (30)
Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? (2016) (30)
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response (2014) (29)
Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome (2011) (28)
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study (2018) (28)
MALT Lymphomas. (2001) (28)
MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial (2021) (28)
Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas (2000) (28)
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias (2018) (28)
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia (2012) (27)
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) (2011) (27)
Extranodal lymphomas : pathology and management (2008) (27)
The VIMOS-VLT Deep Survey: evolution in the halo occupation number since z∼ 1★ (2010) (27)
Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma (1995) (26)
Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma. (1991) (26)
Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells (2010) (25)
Are antibiotics the treatment of choice for gastric lymphoma? (2004) (25)
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study (2011) (25)
First-line treatment of follicular lymphoma–a patient-oriented algorithm (2009) (25)
Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies (2014) (25)
Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland (2009) (25)
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. (2020) (24)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (2016) (24)
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B‐cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group‐37 study (2017) (24)
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. (1996) (24)
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. (2012) (24)
Report of the 6th International Workshop on PET in lymphoma (2017) (24)
Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (2009) (23)
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. (2020) (23)
BCL10 gene mutations rarely occur in lymphoid malignancies (2000) (23)
Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. (2014) (23)
Bayesian network data imputation with application to survival tree analysis (2016) (22)
18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (2012) (22)
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma (2010) (22)
Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype (2012) (22)
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. (2021) (22)
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial (2013) (22)
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10 (2014) (21)
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma (2016) (21)
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models (2019) (21)
Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. (2020) (21)
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. (2021) (20)
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance (2018) (20)
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index (2022) (20)
Management of elderly patients with hematological neoplasms. (2007) (20)
The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. (2014) (20)
Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model. (1997) (20)
Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach (1998) (20)
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas (2018) (20)
Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy‐type T‐cell lymphoma (2008) (20)
Promoter methylation patterns in Richter syndrome affect stem‐cell maintenance and cell cycle regulation and differ from de novo diffuse large B‐cell lymphoma (2013) (20)
Prognostic models for diffuse large b‐cell lymphoma (2000) (19)
International Collaborative Group against Primary CNS Lymphomas. (2003) (19)
Prognostic impact of monocyte count at presentation in mantle cell lymphoma (2013) (19)
Genome‐wide high resolution DNA profiling of hairy cell leukaemia (2013) (19)
Prognostic models for primary mediastinal (thymic) B‐cell lymphoma derived from 18‐FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study (2017) (19)
The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15‐ICML workshop on ctDNA (2019) (18)
Toward new treatments for mantle-cell lymphoma? (2013) (18)
A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) (2014) (18)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. (2020) (18)
Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. (1999) (18)
The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B‐cell and diffuse large B‐cell histologies (2002) (18)
Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature (1997) (17)
Management of rare forms of lymphoma (1998) (17)
Cyclin D 3 is a target gene of t ( 6 ; 14 ) ( p 21 . 1 ; q 32 . 3 ) of mature B-cell malignancies (2001) (17)
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. (2022) (17)
Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group (2012) (17)
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. (2012) (16)
Primary extranodal lymphoma of skeletal muscles: a report of four cases. (1998) (16)
Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. (1999) (16)
Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls (2011) (16)
Microsatellite instability in gastric MALT lymphomas and other associated neoplasms. (1999) (16)
Diagnosis and treatment of follicular lymphoma. (2011) (15)
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. (2013) (15)
Treatment of gastric marginal zone lymphoma of MALT type (2010) (15)
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma (2018) (15)
A major merger origin for the high fraction of galaxies at 2 (2016) (15)
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy (2013) (15)
Unmet needs in the scientific approach to older patients with lymphoma (2017) (14)
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study) (2014) (14)
Hodgkin and non-Hodgkin lymphomas during pregnancy. (2008) (14)
Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial. (2015) (14)
Understanding the group of peripheral T-cell lymphomas, unspecified. (2005) (14)
Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. (1999) (14)
Genome-wide promoter methylation of hairy cell leukemia. (2019) (14)
Genome-wide DNA profiling of HIV-related B-cell lymphomas. (2013) (14)
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy (2020) (14)
Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? (2006) (14)
Epidemiology and management of lymphoma in low‐income countries (2011) (14)
Mantle cell lymphoma (2004) (13)
ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis (2004) (13)
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022) (13)
Absence of NOTCH1 gene mutations in MALT lymphomas (2012) (13)
Management of non-Hodgkin lymphomas arising at extranodal sites. (2010) (13)
Chromosome instability and translocation t(11;18) in primary gastric marginal zone B‐cell lymphoma of MALT‐type (2007) (13)
Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. (1997) (13)
Open questions in the management of mantle cell lymphoma. (2013) (13)
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents (2019) (13)
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10 (2016) (12)
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK) (2020) (12)
Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review (2018) (12)
5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies (2014) (12)
Clonality assessment in blood of patients with mantle cell lymphoma. (1999) (12)
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas (2019) (12)
Integrated profiling of diffuse large B‐cell lymphoma with 7q gain (2011) (12)
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array (2012) (12)
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. (2016) (12)
The changing paradigm of chronic lymphocytic leukemia management. (2013) (11)
Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study (2010) (11)
Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume (2019) (11)
Fine-needle aspiration to diagnose primary thyroid lymphoma: a systematic review and meta-analysis. (2019) (11)
I. Description and first results (1997) (11)
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax (2019) (11)
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. (2018) (11)
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. (2020) (11)
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial (2020) (11)
Risk factors for renal toxicity after inpatient cisplatin administration (2020) (11)
THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE (2017) (11)
Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells (2012) (11)
Polarographic Assay of Submicrogram Quantities of Cis-Dichlorodiamineplatinum (II) in Biological Samples (1983) (11)
Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08 (2016) (10)
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. (2021) (10)
Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions (2018) (10)
Primary CNS lymphomas prognosis. (2007) (10)
Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type) (2002) (10)
Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices (2013) (10)
The VIMOS VLT deep survey. The K-band follow-up in the 0226-04 field (2008) (10)
Genetic lesions in diffuse large B-cell lymphomas. (2015) (10)
Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia (2018) (10)
Halogenohydrido and halogenocarbonyl-hydrido complexes of rhenium (1969) (10)
Ten years of international primary CNS lymphoma collaborative group studies. (2013) (10)
Altered gene expression and oncogenesis of B-cell neoplasia. (1991) (9)
ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma (2003) (9)
Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. (2009) (9)
Marginal zone lymphoma: present status and future perspectives. (2022) (9)
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis (2008) (9)
Association of gastric and Waldeyer's ring lymphoma: a molecular study (2000) (9)
Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015 (2017) (9)
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) (2013) (9)
Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial (2020) (9)
The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years (2011) (9)
Another Piece of the MALT Lymphomas Jigsaw. (2005) (8)
Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome (2019) (8)
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03 (2009) (8)
Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma. (2003) (8)
Mantle cell lymphoma: new treatments targeted to the biology. (2002) (8)
Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication. (2005) (8)
Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy (2017) (8)
99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS (2008) (8)
Genetic alterations underlying the pathogenesis of MALT lymphoma. (2002) (8)
Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma. (2000) (8)
A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies (2014) (8)
The ESO Slice Project (ESP) galaxy redshift survey IV. A discussion of systematic biases in galaxy redshift determinations (1998) (8)
Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma (2012) (8)
Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma (2018) (8)
Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis (2013) (7)
Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines (2000) (7)
Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study. (2006) (7)
The ESO Slice Project (ESP) galaxy redshift survey: I. Description and First Results (1997) (7)
Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. (1996) (7)
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis (2021) (7)
Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells (2013) (6)
Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment (2020) (6)
Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG. (2006) (6)
Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. (2011) (6)
CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. (2015) (6)
528 The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL) (2012) (6)
BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL) (2011) (6)
The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL) (2012) (6)
The novel atypical retinoid ST5589 down‐regulates Aurora Kinase A and has anti‐tumour activity in lymphoma pre‐clinical models (2015) (5)
The impact of histopathologic diagnosis on the proper management of testis neoplasms (2008) (5)
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland (2020) (5)
The most massive, passive, and oldest galaxies at 0.5 < z < 2.1: Downsizing signature from galaxies selected from MgUV index (2019) (5)
Comprar Extranodal Lymphomas | Emanuele Zucca | 9780415426763 | Informa Healthcare (2008) (5)
The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models (2016) (5)
Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How (2016) (5)
Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type (2018) (5)
A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis (2015) (5)
Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas (2008) (5)
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study (2022) (5)
Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance (2019) (5)
The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium (2019) (5)
Consensus conferences : guidelines on malignant lymphoma . part 2 : marginal zone lymphoma , mantle cell lymphoma , peripheral T-cell lymphoma (2013) (5)
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab (2021) (5)
Power spectrum analysis of the ESO Slice Project galaxy redshift survey (2000) (5)
Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors (2018) (4)
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. (2021) (4)
Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (4)
Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers (2011) (4)
IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT) (2017) (4)
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents (2016) (4)
Projeto de célula-T: estudo internacional, longitudinal de pacientes com linfoma de célula-T periférica agressivo (2009) (4)
The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL) (2017) (4)
Cell cycle regulation and the function of cancer genes. (1995) (4)
Management of lymphomas at extranodal locations (2010) (4)
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES (2019) (4)
Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas (2018) (4)
Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
The VIMOS-VLT Deep Survey: Dependence of galaxy clustering on stellar mass (2007) (4)
Abstract 4182: The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma (2017) (4)
Abstract B77: The BET bromodomain inhibitor OTX015 (MK-8628) in mantle cell lymphoma (MCL): in vivo activity and identification of novel combinations to overcome adaptive resistance (2015) (4)
Aplidin® (Plitidepsin) Activity In Peripheral T-Cell Lymphoma (PTCL): Final Results (2010) (4)
Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma (2020) (4)
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas (2021) (3)
A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function. (2007) (3)
Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial. (2008) (3)
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type (2020) (3)
Novel acquisitions on biology and management of transformed follicular lymphoma (2018) (3)
Extrinsic compression of the pulmonary artery by primary mediastinal large B‐cell lymphoma (2009) (3)
Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals (2018) (3)
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. (2012) (3)
ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients. (1999) (3)
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR‐ABL inhibitors in lymphomas (2011) (3)
Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma (2019) (3)
Prognostic impact of monocyte count at presentation in mantle cell lymphoma – response to George et al (2014) (3)
Syk expression patterns differ among B-cell lymphomas. (2010) (3)
METABOLIC HETEROGENEITY OF BASELINE 18‐FDG PET‐CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA. (2017) (3)
LYMPHOID NEOPLASIA PRDM 1 / BLIMP 1 is commonly inactivated in anaplastic large T-cell lymphoma (2013) (3)
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION (2019) (3)
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas (2019) (3)
The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors (2012) (3)
DNA fingerprinting of low-grade extranodal marginal zone B-cell lymphoma (of MALT type) (1999) (3)
A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals (2007) (3)
Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib (2017) (3)
Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG (2011) (3)
Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103 (2018) (3)
The VIRMOS-VLT Deep Survey: a progress report (2003) (3)
SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS (2019) (3)
Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529 (2016) (3)
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis (2022) (3)
Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma (2016) (3)
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS (2019) (2)
Indolent lymphoma 295 ANALYSIS OF PROGNOSTIC FACTORS IN 424 MALT LYMPHOMA PATIENTS TREATED IN THE IELSG-19 MULTICENTER RANDOMISED STUDY (2011) (2)
Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS (2020) (2)
Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models (2015) (2)
EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT (2019) (2)
Chapter 21 – Marginal Zone B-Cell Lymphomas (2006) (2)
Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma (2020) (2)
Enzymuria in Carboplatin Nephrotoxicity (1987) (2)
Gastric MALT lymphomas prospective LY03 randomised cooperative trial: preliminary results of the molecular follow-up (2001) (2)
The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas (2015) (2)
Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma (2019) (2)
Long Term Outcome of Gastric MALT Lymphoma Patients Treated with Anti-Helicobacter (Antibiotic and Proton-Pump Inhibitor) Regimens. (2007) (2)
Bendamustine in lymphomas: More to combine? (2007) (2)
Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group. (2016) (2)
Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. (2007) (2)
Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL). (2013) (2)
Abstract 2853: Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL) (2018) (2)
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK (2021) (2)
Bacterial infection-driven lymphomagenesis (2022) (2)
INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A) (2019) (2)
Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma). (2009) (2)
Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion. (2007) (2)
Extranodal Marginal Zone B-Cell Lymphoma Genotyping by Alu — Polymerase Chain Reaction (2000) (2)
Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials (2022) (2)
Stage-modi ¢ ed international prognostic index e ¡ ectively predicts clinical outcome of localized primary gastric di ¡ use large B-cell lymphoma (1999) (2)
Isolated Brain Parenchyma Relapse of Non-Hodgkin’s Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). (2006) (2)
A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression (2018) (2)
Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group. (2016) (2)
Lymphoma: MALT and other marginal zone lymphomas (2013) (2)
Non‐negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms (2010) (2)
Marginal Zone Lymphomas. (2020) (2)
Marginal-Zone Lymphomas. (2018) (2)
Distribution of mobilized progenitor cells in the buffy coat of the haemonetics MCS3p cell separator: a study to optimize the collection of progenitors by leukapheresis. (1998) (2)
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type (2021) (2)
Supplementum 216: Diagnosis and treatment of marginal zone lymphoma. (2016) (2)
A Phase II Trial to Investigate the Link with Infectious Agents in Ocular Adnexal Marginal Zone Lymphoma, Especially with Chlamydia Species, and the Antineoplastic Effects of Doxycycline (Ielsg#27) (2010) (2)
Challenging issues in the management of extranodal lymphomas (2008) (2)
Can we increase the cure rate in elderly patients with diffuse large cell lymphomas? (1993) (2)
Abstract 2651: A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models (2017) (2)
Gastric MALT lymphomas, new insight and still unanswered questions. (1998) (2)
Therapeutic use of monoclonal antibodies: a new era? (1998) (2)
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43) (2022) (2)
Helicobacter pylori Eradication in Gastric: Mucosa-Associated Lymphoid: Tissue Lymphomas (1996) (2)
Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP. (2009) (2)
Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity (2020) (2)
Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures (2019) (2)
COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL) (2008) (1)
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) (2021) (1)
Abstract 4793: Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma (2016) (1)
Extranodal NK/T‐cell lymphoma with leukaemic presentation (2013) (1)
Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells (2008) (1)
Genome-wide DNA proﬁling of marginal zone lymphomas identiﬁes subtype-speciﬁc lesions with an impact on the clinical outcome (2011) (1)
Radiomics in Malignant Lymphomas (2021) (1)
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas (2020) (1)
MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature (2020) (1)
In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas. (2006) (1)
Session 4 : lymphoma genomics (2011) (1)
Cutaneous T-cell lymphoma: from genetics to clinical practice. (2007) (1)
Genomic profiles of MALT lymphomas: variability across anatomic sites Running title: Genomic lesions in MALT lymphomas (2011) (1)
The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response (2014) (1)
Commentary Biology and treatment of MALT lymphoma: The state-of-the-art in 1996 A workshop at the 6th International Conference on Malignant Lymphoma (2005) (1)
DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA (2021) (1)
lymphocytic leukemia to Richter syndrome Two main genetic pathways lead to the transformation of chronic (2013) (1)
Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features. (2009) (1)
Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. (1999) (1)
Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment. (2017) (1)
IGHD3‐3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia (2010) (1)
Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia (2022) (1)
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma (2022) (1)
Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study (2017) (1)
Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas (2015) (1)
SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups (2010) (1)
Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma (2016) (1)
A Phase II Study to Investigate the Prevalence of Infectious Agents in Ocular Adnexae Marginal Zone Lymphoma (Oamzl) and the Efficacy of Antibiotic Therapy (Ielsg#27 Trial) (2011) (1)
BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma (2014) (1)
The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23). (2005) (1)
SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL). (2009) (1)
Faculty Opinions recommendation of Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. (2018) (1)
IELSG Phase II Studies of Bortezomib in Malt Lymphomas. (2007) (1)
The seventh Lugano conference — basic science, translational and clinical research in the lymphoma field: The challenge goes on (2000) (1)
952PPATIENTS WITH HODGKIN'S LYMPHOMA HAVE A SIGNIFICANTLY BETTER OUTCOME IF TREATED WITHIN A CLINICAL TRIAL. (2014) (1)
The VIMOS-VLT Deep Survey. Beyond color bimodality: the mix of galaxy populations up to z~2 (2006) (1)
Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial (2015) (1)
Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project. (2012) (1)
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors (2023) (1)
International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia (2019) (1)
Proceedings of the VIIth international conference on malignant lymphoma, 2-5 June, 1999, Lugano, Switzerland : selected papers (2000) (1)
Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma (2017) (1)
Reply to G. Keramida et al. (2015) (1)
Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBB/EP300 inhibitors in diffuse large B cell lymphoma (2019) (1)
Dmax: A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome? (2022) (1)
DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) (2017) (1)
Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial (2019) (1)
Genome Wide-DNA Profiling of HIV-Related Non-Hodgkin Lymphomas: Implications for Disease Pathogenesis and Histogenesis. (2007) (1)
SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS) (2011) (1)
The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma (2014) (1)
A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) . (2008) (1)
MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) ‐ INTERIM ANALYSIS OF IELSG46 STUDY (2019) (1)
6005 ORAL Are we changing the survival of follicular lymphomas? Patterns of outcome in the patients treated at the Oncology Institute of Southern Switzerland from 1979 to 2006 (2007) (1)
Response: CNS prophylaxis in MCL (2009) (1)
The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas (2016) (1)
Tailoring treatment for MALT lymphoma patients: where do we stand now? (2017) (1)
4 Marginal zone B-cell lymphomas (2010) (1)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy (2014) (1)
The ESO Slice Project (ESP) Redshift Survey (1998) (1)
PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL (2019) (1)
ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma (2016) (1)
Treatment for patients with indolent and mantle cell lymphoma (2013) (1)
Genome Wide-DNA Profiling of Richter’s Syndrome-Diffuse Large B-Cell Lymphoma (RS-DLBCL): Differences with De Novo DLBCL and Possible Mechanisms of Transformation from Chronic Lymphocytic Leukemia (CLL). (2008) (1)
A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL. (2019) (1)
Genome-Wide Promoter Methylation Of Hairy Cell Leukemia (HCL) (2013) (1)
Use of epirubicin to treat diffuse large B-cell lymphoma. (2019) (1)
Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes (2013) (1)
Abstract CT402: A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL) (2014) (0)
816 Development of an active CHOP-modified regimen which allows more continuous and better tolerated treatment for diffuse aggressive non-hodgkin's lymphomas (NHL) (1995) (0)
The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL) (2016) (0)
Faculty of 1000 evaluation for An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. (2018) (0)
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA (2019) (0)
Nephrotic syndrome after cisplatin plus cyclophosphamide for ovarian carcinoma. (1986) (0)
Star-forming Galaxies in the VVDS-VLA-02h Deep Field (2005) (0)
Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method (2022) (0)
Reply to the letter to the editor 'Survival in young adults diagnosed with follicular lymphoma' by Calvo et al. (2016) (0)
Integral Field Unit : data reduction methods and quality assessment (2005) (0)
subtype-specific lesions with an impact on the clinical outcome Genome-wide DNA profiling of marginal zone lymphomas identifies (2011) (0)
Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax (2016) (0)
[Supradiaphragmatic right-sided space-occupying lesion]. (1997) (0)
Faculty Opinions recommendation of Notch signalling in context. (2018) (0)
VizieR Online Data Catalog: 1.4GHz obs. and optical ident. in A3558 (Giacintucci+, 2004) (2004) (0)
THE ADDITION OF THIOTEPA AND RITUXIMAB TO HIGH DOSES OF ANTIMETABOLITES SIGNIFICANTLY IMPROVES OUTCOME IN PRIMARY CNS LYMPHOMA: THE FIRST RANDOMIZATION OF THE IELSG #32 TRIAL (2015) (0)
The violent environment of the Shapley Concentration: a multiwavelength view (2000) (0)
Recommended Procedures for Initial Staging and Follow-Up of Patients With Nongastric MALT Lymphoma (2017) (0)
PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL) (2022) (0)
Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes (2014) (0)
Prognost ic Scor ing System for Primary CNS Lymphomas : The Internat ional Extranodal Lymphoma Study Group Exper ience (2002) (0)
In Reply to Adams and Kwee. (2017) (0)
with other anti-lymphoma targeted agents The BTK inhibitor zanubrutinib ( BGB-3111 ) demonstrated synergies Version 2 HAEMATOL / 2018 / 214759 Haematologica Bertoni (2019) (0)
CNS prophylaxis in MCL (2009) (0)
Faculty of 1000 evaluation for From hepatitis C virus infection to B-cell lymphoma. (2018) (0)
Erratum: The publisher would like to apologize on behalf of the authors. Since publication of the ORIGINAL ARTICLE: CLINICAL (Leukemia and Lymphoma (2009) 50(6) 925-931 (2010) (0)
Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas. (2005) (0)
VizieR Online Data Catalog: ESO Slice Project. VI. Groups of Galaxies. (Ramella+ 1999) (1998) (0)
9216 Incidence and outcome of histological transformation in a single-institution cohort of patients with follicular lymphoma (2009) (0)
Abstract 796: The BTK inhibitor BGB-3111 is synergistic with other anti-lymphoma targeted agents (2018) (0)
Redshift-space distortions as a probe of dark energy (2007) (0)
Erratum: Early stage gastric diffuse large B-cell lymphomas: Results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (Leukemia and Lymphoma (2009) 50:6 (925-931)) (2009) (0)
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103 (2022) (0)
Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia (2016) (0)
ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience (2004) (0)
Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma (2018) (0)
842P Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models (2021) (0)
Trends in survival from cancer of the corpus uteri in Switzerland (2018) (0)
Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: A Multicenter Retrospective Analysis. (2004) (0)
neuro-oncology 897P CLINICAL FEATURES, OUTCOME AND LATE EFFECTS IN MALIGNANT INTRACRANIAL GERM CELL TUMORS. (2006) (0)
Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. (2023) (0)
57 High-resolution genomic profiling of 533 B-cell lymphomas defines distinct tumor signatures, genomic aberrations correlated with outcome and pathogenetic subgroups (2010) (0)
Faculty of 1000 evaluation for 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. (2018) (0)
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma (2022) (0)
16th International Conference on Malignant Lymphoma Virtual Edition 18 ‐ 22 June, 2021 (2021) (0)
Faculty Opinions recommendation of Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. (2007) (0)
The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL) (2016) (0)
The galaxy density field at high redshift The first large redshift surveys of the local Universe (2008) (0)
Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma (2022) (0)
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (2019) (0)
Mass-Transfer Induced Activity in Galaxies: Star–Forming Galaxies and Large–Scale Structure ( Poster paper ) (1994) (0)
Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: a Retrospective Analysis of Twenty-six Patients Treated in (1994) (0)
The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL) (2015) (0)
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY (2021) (0)
Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab. (2014) (0)
ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. (2004) (0)
Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents (2019) (0)
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial (2022) (0)
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. (2022) (0)
Erratum: Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers (Annals of Oncology (2001) vol. 12 (7) (987-990)) (2001) (0)
Genomic aberrations aff ecting the outcome of immunodefi ciency-related diff use large B-cell lymphoma (2012) (0)
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia (2012) (0)
ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL‐LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (0)
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA (2019) (0)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) AMIEE.JACKSON, a MICHAELMIAN, c,d CHRISTINAKALPADAKIS, e GERASSIMOSA.PANGALIS, f ANASTASIOSSTATHIS, g ELENAPORRO, g ANNARITACONCONI, h (2015) (0)
LYMPHOID NEOPLASIA DNA methylation pro ﬁ ling identi ﬁ es two splenic marginal zone lymphoma subgroups with different clinical and genetic features (2015) (0)
Abstract P073: Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors (2021) (0)
Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses. (2016) (0)
Prevalence of hepatitis C virus and GB-C virus infection among patients with B-cell non-Hodgkin's lymphoma: A case-control study of the International Extranodal Lymphoma Study Group (2006) (0)
In reply. (2014) (0)
A phase II trial addressing the prevalence of chlamydial infection and eradication efficacy of antibiotic therapy in marginal zone lymphoma (OAMZL) and other lymphoproliferative disorders of the ocular adnexae (LPDOA) (2010) (0)
Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL). (2007) (0)
The VVDS: early results on the large scale structure distribution of galaxies out to z ~ 1.5 (2005) (0)
Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations (2015) (0)
Lymphomas of the gastrointestinal tract (2008) (0)
Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway (2011) (0)
Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations (2013) (0)
LYMPHOID NEOPLASIA Deregulation of ETS 1 and FLI 1 contributes to the pathogenesis of diffuse large B-cell lymphoma (2013) (0)
MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma) (2013) (0)
Who should receive myeloablative therapy for diffuse large B-cell lymphoma? (2008) (0)
Chronic lymphocytic leukemia subset expressing mutated IGHV3-23 has a peculiar clinical and biological features (2010) (0)
00 12 25 4 v 1 1 2 D ec 2 00 0 Optical / Infrared Survey of Galaxy Clusters (2000) (0)
SAKK 36 / 13 – Ibrutinib and bortezomib and ibrutinib maintenance for relapsed / refractory mantle cell lymphoma : an ongoing trial (2018) (0)
Prognosis of adult acute myeloid leukemia in Southern Switzerland: A population-based analysis (2005) (0)
IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin (2010) (0)
Genome‐wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas (2014) (0)
No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials (2014) (0)
CD30 and lymphomas: the clue for four? (2019) (0)
Intravascular lymphoma of the CNS (2012) (0)
Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity (2018) (0)
Histologic Transformation in Marginal Zone Lymphomas (2012) (0)
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA (2021) (0)
PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG (2010) (0)
Survival of Patients Autografted for Chemosensitive Hodgkin Lymphoma After Failure of Upfront BEACOPP Escalated Versus ABVD-Like Regimens (2011) (0)
Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?. (2009) (0)
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix) (2016) (0)
Faculty Opinions recommendation of Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma. (2018) (0)
phase Ii Study For The Evaluation Of Feasibility, Activity And Safety Of Bendamustine And Ofatumumab In Combination In Marginal Zone B-cell Lymphomas (mzl) : 198 (2015) (0)
Optical/Infrared Survey of Galaxy ClustersDeep Fields (2000) (0)
Treatment of Helicobacter pylori-associated lymphomas (2009) (0)
Clinical Lymphoma & Myeloma November 2005 Primary Pulmonary Lymphoma (0)
The ESO Slice Project (ESP) galaxy redshift survey: VI Groups of Galaxies (1998) (0)
Abstract 1894: Identification of novel OTX015-containing combinations for lymphoma treatment (2018) (0)
MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT (2013) (0)
z ∼ 0.9 (2008) (0)
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib (2023) (0)
Abstract 492: Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models (2023) (0)
Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma (2022) (0)
AND FLIPI ARE NOT APPLICABLE IN PATIENTS WITH MALT LYMPHOMA (2008) (0)
Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma (2018) (0)
HELICOBACTER PYLORI ERADICATION IN GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS. AUTHORS' REPLY (1996) (0)
Preface: why this special series on marginal zone lymphomas? (2021) (0)
How I treat How I treat mantle cell lymphoma (2009) (0)
MAIN ENTITIES/LOCATIONS (2008) (0)
The Luminosity Function and Mean Galaxy Density from the ESO Slice Project (ESP) (1998) (0)
The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study) (2008) (0)
Marginal-Zone Lymphomas. Reply. (2022) (0)
ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATION (2021) (0)
lymphoma biology 273 EXONIC MUTATIONS ARE COMMONLY FOUND IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA AND FAMILY MEMBERS OF WM PATIENTS WITH HYPER-IGM SYNDROME (2008) (0)
Lymphoma: MALT lymphoma and other marginal zone lymphomas (2007) (0)
Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors (2014) (0)
Early Results from the VIMOS VLT Deep Survey (2003) (0)
Abstract A129: Novel histone deacetylase inhibitors ITF-A and ITF-B exhibit efficacy in preclinical models of mature B-cell lymphomas. (2013) (0)
Clinical Relevance of the Dose of Cytarabine In the Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Chemotherapy Combination (2010) (0)
Faculty Opinions recommendation of Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. (2010) (0)
Application of genomic real-time PCR to characterise 11q deletions in mantle cell lymphoma and chronic lymphocytic leukaemia (2001) (0)
A Multicentre Phase II Trial Testing Gemcitabine in the Treatment of Patients with Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma: SAKK 36/03. (2007) (0)
Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas (2015) (0)
Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features (2016) (0)
Faculty Opinions recommendation of Notch and its oncogenic activity in human malignancies. (2018) (0)
Abstract 1017: The BRD-inhibitor OTX015 affects proliferation and gene expression of cells derived from mature lymphoid neoplasms. (2013) (0)
Merging Clusters in the Core of Superclusters: A Multiwavelength View (2005) (0)
[Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans]. (1985) (0)
Abstract 799: The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent (2018) (0)
Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Deregulating ETS1 and FLI1 (2011) (0)
ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (0)
Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience. (2007) (0)
Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial. (2010) (0)
Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma? (2017) (0)
Faculty of 1000 evaluation for Mechanisms of NF-κB deregulation in lymphoid malignancies. (2018) (0)
Early progression of disease (POD24) as survival predictor in MALT lymphoma. (2019) (0)
VizieR Online Data Catalog: Physical properties of VVDS galaxies (Lamareille+, 2009) (2009) (0)
Risk factors for renal toxicity after inpatient cisplatin administration (2020) (0)
What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts (2022) (0)
External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL (2022) (0)
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA (2019) (0)
Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response (2014) (0)
CLOSED WORKSHOP: "FOLLICULAR LYMPHOMA: RECENT INSIGHTS AND FUTURE DIRECTIONS (MOVING TOWARDS BIOLOGY-DRIVEN TREATMENTS?)"* (2015) (0)
Bajovic Detecting random walks on graphs with heterogeneous sensors 10 10 : 40 coffee break Action Conference — session chair (0)
Non‐Hodgkin Lymphomas (2006) (0)
PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) (2016) (0)
Prognostic S coring S ystem f or P rimary C NS L ymphomas: The I nternational E xtranodal L ymphoma S tudy G roup Experience (2003) (0)
Abstract 1701: The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL) (2017) (0)
outcome Analysis Of Diffuse Large B-cell Lymphoma (dlbcl) In Hiv-infected And Immunocompetent (ic) Patients: The Swiss Hiv Cohort Study (shcs) : 218 (2015) (0)
Results from a Multiwavelength Survey in the Shapley Concentration (1998) (0)
aggressive lymphoma 182 BENEFIT OF ANTI-VIRAL AND PNEUMOCYSTIS CARINII PROPHYLAXIS IN PATIENTS TREATED WITH R-CHOP (2008) (0)
Multiwavelength view of merging clusters (2004) (0)
Bronchial-associated lymphoid tissue (BALT) lymphoma: a retrospective analysis. (2006) (0)
A galaxy redshift survey in the South Galactic Pole region (1992) (0)
Single Cell RNA-Seq of Extranodal Marginal Zone Lymphoma (MZL) Identifies Site-Specific and Shared Features in Both B and T Cell Components (2022) (0)
568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM) (2014) (0)
R11Survival and prognostic factors in very elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of 281 patients over 80 years (2015) (0)
Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH (2012) (0)
IN12 Marginal zone lymphomas (2012) (0)
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms (2023) (0)
Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG) (2021) (0)
Clustering evolution up to z = 2 of a spectroscopic sample of galaxies selected from Spitzer IRAC 3 . 6 μ m and 4 . 5 μ m photometry (2007) (0)
Where Do We Stand in the Genomics of Lymphomas (2013) (0)
Testing gravity on large scales. The skewness of the galaxy distribution at z~1 (2008) (0)
Plitidepsin is active in peripheral T-cell lymphoma: a subset analysis from an ongoing multicenter phase II trial (2009) (0)
High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?. (2009) (0)
COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS (2017) (0)
Rapid publication 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage IH-FV non-Hodgkin's lymphoma (2004) (0)
Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping (2000) (0)
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP (2008) (0)
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma. (2022) (0)
A Systematic Review and a Survey Both Reveal Wide Heterogeneity across Trials and Investigators on Time-to-Event Endpoints Definitions in Marginal Zone Lymphoma (2021) (0)
CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK Pathway (2021) (0)
A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers (2022) (0)
ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY (2021) (0)
Abstract 4796: EG-011 is a novel small molecule within vitroandin vivoanti-tumor activity against lymphoma (2019) (0)
Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models (2015) (0)
Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia. (2007) (0)
The clinical significance of molecular monitoring in the management of patients with follicular lymphomas (1994) (0)
Erratum: ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma (Leukemia & Lymphoma (2003) vol. 44 (5) (801-806)) (2003) (0)
PET imaging of lymphomas (2021) (0)
PET 215 QUANTITATIVE INTERIM PET IS MORE ACCURATE THAN QUALITATIVE ASSESSMENT IN PREDICTING OUTCOME IN DLBCL (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Emanuele Zucca?

Emanuele Zucca is affiliated with the following schools:

University of Insubria
Università della Svizzera italiana
University of Milan
University of Verona
University of Bern
Sapienza University of Rome
University of Barcelona
University of Bologna
University of Zurich
King's College London